Table 2.
Parameters | Progressive | Indeterminate | Regressive | P value |
Pretreatment, n (%) | 15 (65) | 7 (30) | 1 (4) | |
Age (yr) | 50.3 ± 12.3 | 43.9 ± 12.5 | 27.0 | 0.154 |
Males, n (%) | 6 (40) | 3 (43) | 0 (0) | 0.709 |
ALT (U/L) | 66 (57) | 48 (38) | 50 (0) | 0.469 |
TBil (μmol/L) | 14.0 (8.0) | 12.0 (6.0) | 9.0 (0.0) | 0.642 |
Albumin (g/L) | 44.0 ± 3.9 | 47.0 ± 3.1 | 45.0 | 0.233 |
Platelets (× 103 μL) | 129.3 ± 60.2 | 188.0 ± 51.5 | 268.0 | 0.024 |
INR | 1.04 (0.16) | 1.00 (0.2) | 1.00 (0.00) | 0.307 |
HCV RNA (log IU/L) | 6.01 ± 0.66 | 6.46 ± 0.90 | 6.60 | 0.375 |
LSM, kPa | 8.8 (14.8) | 6.6 (2.9) | 6.6 (0.0) | 0.331 |
HAI score, n (%) | 0.070 | |||
0-3 | 0 (1) | 1 (14) | 0 (0) | |
4-6 | 1 (7) | 2 (29) | 1 (100) | |
7-9 | 4 (27) | 3 (43) | 0 (0) | |
≥ 10 | 10 (67) | 1 (14) | 0 (0) | |
Ishak score, n (%) | 0.072 | |||
3-4 | 4 (27) | 5 (71) | 1 (100) | |
5-6 | 11 (73) | 2 (29) | 0 (0) | |
Posttreatment, n (%) | 5 (22) | 9 (39) | 9 (39) | |
Age (yr) | 50.4 ± 12.0 | 47.8±14.1 | 45.4 ± 13.4 | 0.802 |
Males, n (%) | 1 (20) | 3 (33) | 5 (56) | 0.384 |
ALT (U/L) | 25 (21) | 17 (8) | 15 (15.5) | 0.340 |
TBil (μmol/L) | 19 (10) | 10 (6) | 14 (9) | 0.149 |
Albumin (g/L) | 44.0 ± 4.2 | 44.9 ± 1.9 | 46.0 ± 1.8 | 0.353 |
Platelets (× 103 μL) | 156.4 ± 63.3 | 184.4 ± 80.3 | 151.1 ± 65.8 | 0.552 |
INR | 1.13 (0.15) | 1.00 (0.14) | 1.09 (0.15) | 0.052 |
LSM, kPa | 11.5 (22.8) | 7.8 (7.4) | 6.8 (5.2) | 0.683 |
HAI score, n (%) | 0.338 | |||
0-3 | 1 (20) | 4 (44) | 6 (67) | |
4-6 | 2 (40) | 4 (44) | 3 (33) | |
7-9 | 1 (20) | 0 (0) | 0 (0) | |
≥ 10 | 1 (20) | 1 (11) | 0 (0) | |
Ishak score, n (%) | 0.339 | |||
3-4 | 2 (40) | 6 (67) | 6 (67) | |
5-6 | 3 (60) | 3 (33) | 3 (33) |
ALT: Alanine aminotransferase; TBil: Total bilirubin; INR: International normalized ratio; HCV: Hepatitis C virus; LSM: Liver stiffness measurement; HAI: Histology activity index.